文献速递系统性红斑狼疮其他结缔组织病

抑制内皮细胞BRD4通过相互作用FLI-1部分缓解狼疮肾炎

Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis Partly Through Interacting With FLI-1.
PubMed 文献 · Arthritis Rheumatol · 2026-09-07

该研究探讨BRD4在狼疮肾炎(LN)进展中的作用及靶向BRD4的治疗潜力。在LN患者和MRL/Lpr小鼠肾内皮细胞中BRD4表达升高,使用BET抑制剂NHWD870或内皮靶向BRD4 shRNA-AAV可改善LN特征。机制部分与BRD4和FLI-1相互作用相关。

要点

  • LN患者和MRL/Lpr小鼠肾内皮细胞BRD4表达升高。
  • BET抑制剂NHWD870或内皮靶向BRD4 shRNA-AAV改善MRL/Lpr小鼠LN特征。
  • BRD4与FLI-1共定位并相互作用,参与LN发病。

核心结论

  • 内皮细胞BRD4升高参与LN发病,部分与和FLI-1相互作用相关,靶向内皮BRD4可能成为LN治疗策略。

研究设计与样本

  • 研究采用MRL/Lpr小鼠狼疮模型,通过内皮细胞靶向BRD4 shRNA-AAV抑制内皮BRD4。
  • 体外使用人肾小球内皮细胞(GECs),结合RNA测序、染色质免疫沉淀PCR和蛋白-蛋白相互作用实验。

主要发现

  • LN患者和狼疮小鼠模型肾内皮细胞BRD4表达增加。
  • BET抑制剂NHWD870治疗显著改善MRL/Lpr小鼠LN特征,包括减少病变、IgG和C3沉积、免疫浸润及改善肾组织超微结构。
  • BRD4 shRNA-AAV治疗显著改善MRL/Lpr小鼠LN标志特征,包括蛋白尿、肾脏组织学和超微形态、IgG和C3沉积及免疫浸润。
  • BRD4升高导致与LN相关的多条通路改变,并促进GECs通透性和免疫反应,与FLI-1相互作用相关。
  • BRD4 shRNA-AAV治疗减弱MRL/Lpr小鼠FLI-1表达,BRD4与FLI-1在肾内皮细胞共定位,LN患者FLI-1表达升高。

临床怎么用

  • 靶向内皮BRD4(如BET抑制剂或内皮靶向shRNA-AAV)可能改善LN特征。
  • BRD4与FLI-1相互作用可作为LN机制研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Bromodomain 4 (BRD4) could be a therapeutic target in various diseases. We sought to investigate its role in lupus nephritis (LN) progression and explore whether targeting BRD4 could serve as a therapeutic approach for LN. METHODS: BRD4 expression in renal cells was evaluated by immunofluorescence. Inhibition of endothelial BRD4 in mice was conducted by using BRD4 short hairpin RNA adeno-associated virus (shRNA-AAV) targeting endothelial cells (ECs). Mouse lupus models were MRL/Lpr mice. Human glomerular ECs (GECs) coupled with RNA sequencing, chromatin immunoprecipitation polymerase chain reaction, and protein-protein interaction assays were performed to define underlying mechanisms. RESULTS: BRD4 expression was increased in renal ECs in patients with LN and in mouse lupus models. Bromodomain and extraterminal inhibitor NHWD870 treatment greatly improved the features of LN in MRL/Lpr mice as evidenced by reduced lesions, IgG and C3 deposition, immune infiltration, and improved ultrastructural morphology in renal tissues. BRD4 shRNA-AAV treatment robustly ameliorated the hallmark features of LN in MRL/Lpr mice including proteinuria, histologic and ultrastructural morphology of kidney, and IgG and C3 deposition and immune infiltration in kidney in MRL/Lpr mice. Elevated BRD4 led to changes in many pathways linked to LN and promoted permeability and immune responses in GECs, which were associated with their interaction with FLI-1. BRD4 shRNA-AAV treatment attenuated FLI-1 expression in MRL/Lpr mice. BRD4 and FLI-1 were colocalized in renal ECs, and FLI-1 expression was elevated in patients with LN. CONCLUSION: Elevated BRD4 in ECs is involved in LN pathogenesis, which is partly associated with its interaction with FLI-1. Targeting endothelial BRD4 could be a therapeutic strategy for LN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang XK, Chen C, et al. Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis Partly Through Interacting With FLI-1. Arthritis Rheumatol. 2026. PMID: 42703787. doi:10.1002/art.70324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。